Ventilator Associated Bacterial Pneumonia (VABP)NCT07854730

Effect of Ventilator Hyperinflation Combined With Body Positioning on ABG in VAP

A study testing Ventilator hyperinflation and Manual hyperinflation in people with Ventilator Associated Bacterial Pneumonia (VABP) and Critical Illness, run by Al-Zaytoonah University of Jordan at 1 site in Egypt.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

Who is it for?: Ages 40 to 60 years
Conditions the study is for: Ventilator Associated Bacterial Pneumonia (VABP), Critical Illness
What is being tested?: Ventilator hyperinflation and Manual hyperinflation
Type of treatment: Medical device
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 40 participants
Where: 1 siteEgypt
Study dates: 5 Oct 2026to 15 Nov 2026
Phase: Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 40 to 60 years
All sexes
No healthy volunteers
Adult

Who may be able to join

Mechanically ventilated patients ≥ 48 hours
Diagnosed with VAP (clinical + chest X-ray)
Age: 40-60 years
Hemodynamically stable
Unilateral lung involvement

Who cannot join

Bilateral lung disease
Unstable cardiovascular conditions
Contraindications to positioning
Re-intubation cases
Presence of pneumothorax or air leak

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Egypt1 site, 1 recruiting

Mohamed Saied Zidan
Cairo, 11571
Mohamed S Zidan, phd, 01016469801, drmohzidan2015@gmail.com
Mohamed S Zidan, 01016469801
Recruiting

Other trials in Egypt

About this study

Official title: Effect of Ventilator Hyperinflation Combined With Body Positioning on Arterial Blood Gases In Patients With Ventilator-Associated Pneumonia : A Randomized Controlled Trial

This study aims to evaluate the effect of ventilator hyperinflation combined with body positioning on arterial blood gases in patients with ventilator-associated pneumonia. Forty-two mechanically ventilated patients will be randomly assigned into two groups receiving the intervention in either supine or lateral decubitus positions. Arterial blood gases will be assessed over a 6-day intervention period. The findings are expected to provide evidence regarding the optimal positioning strategy to enhance the effectiveness of ventilator hyperinflation in improving gas exchange in critically ill patients.

Conditions: Ventilator Associated Bacterial Pneumonia (VABP), Critical Illness
Being tested: Ventilator hyperinflation, Manual hyperinflation
Medical subject headings: Critical Illness

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Ventilator hyperinflationDevice
a therapeutic technique used by clinicians (Manual or Ventilator Hyperinflation) to clear secretions and recruit collapsed lung tissue, or an inadvertent complic
Manual hyperinflationDevice
a respiratory therapy technique that uses a manual resuscitation bag to deliver larger-than-normal, controlled breaths to clear airway secretions and reopen collapsed lung areas

Study groups in NCT07854730
Study group	Role	What they receive
ventilator hyperinflation from lateral decubitus position	Experimental	This group will receive Ventilator hyperinflation in lateral decubitus position (affected lung uppermost) and Conventional respiratory physiotherapy Receives: Device: Ventilator hyperinflation
Manual hyperinflation for Lateral decubitus position	Experimental	This group will receive manual hyperinflation in Lateral decubitus position and Conventional respiratory physiotherapy Receives: Device: Manual hyperinflation

What is being measured

The primary outcome is the main question the study is designed to answer.

PaCO2
partial pressure of carbon dioxide in arterial blood, measuring how effectively the lungs eliminate carbon dioxide
Measured: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
PaO2
partial pressure of oxygen dissolved in arterial blood plasma, measured through an Arterial Blood Gas (ABG) test.
Measured: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
SaO2
the percentage of oxygen-saturated hemoglobin relative to total hemoglobin in arterial blood, typically measured via an invasive arterial blood gas (ABG) analysis with normal values ranging from 95% to 99%
Measured: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
PaO2/FiO2 (P/F)
a clinical metric used to evaluate oxygenation efficiency and diagnose the severity of acute hypoxemic respiratory failure or Acute Respiratory Distress Syndrome (ARDS).
Measured: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.

Secondary outcomes (1)

Pulmonary compliance
the change in lung volume divided by the change in pressure (Δ V / Δ P). Higher compliance means the lungs stretch easily; lower compliance means they are stiff and harder to inflate
Measured: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

5 Oct 202615 Nov 2026

First posted2 Oct 2026
Study start5 Oct 2026
Primary completion15 Nov 2026 (estimated)
Study completion15 Nov 2026 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Ventilator Associated Bacterial Pneumonia (VABP)Studies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Prevention
Allocation: Randomised
Intervention model: Parallel groups
Masking: Triple blind
Who is masked: Participant, Care provider, Investigator
Enrolment: 40 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07854730
Sponsor's protocol ID: IRB # 14/5/2025-2026
Status last verified: Oct 2026
First submitted: 27 Sep 2026
Last updated: 16 Oct 2026
Results posted: No
FDA-regulated drug: No
FDA-regulated device: No

Interested in taking part?

Each site lists its own contact. Pick the site nearest to you.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

Not yet recruitingPhase 3
Cefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP)
RecruitingPhase 2
ASK0912 Versus Polymyxin B for Injection in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
Ventilator-associated Bacterial Pneumonia (VABP), Hospital-acquired Bacterial Pneumonia (HABP)
Not yet recruitingPhase 3
A Clinical Study of YK-1169 Versus Ceftazidime-Avibactam in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP)
RecruitingPhase 3
Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP)
Not yet recruitingPhase 2
Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
Ventilator Associated Bacterial Pneumonia (VABP), Hospital Acquired Bacterial Pneumonia (HABP)

All Ventilator Associated Bacterial Pneumonia (VABP) trials